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A number of antibody products have now become accepted as effective anti-cancer therapies. Despite being mainly designed to act
by inhibiting functional tumour antigens, there is increasing evidence that Fc-mediated engagement of the immune system is an
important contributor to the efficacy of several of these therapies. The optimisation of this engagement offers the potential not only
to augment efficacy against existing targets, but also to exploit non-functional tumour antigens. Antibodies that achieve efficacy wholly
or predominantly through Fc-mediated mechanisms, represent rich opportunities for future therapeutics in oncology. This mini
review summarises some of the key challenges, which need to be addressed to select the most effective molecules. These include the
identification of optimal antibody characteristics and improvement of the drug discovery process, in particular, the relevance and
predictive power of existing in vitro and in vivo screening methods. Advances in our understanding of tumour immunobiology and
successful application of technologies designed to enhance immune system engagement will further aid this process.
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The successful targeting of a range of cancer types with therapeutic
antibodies, including bevacuzumab, trastuzumab and cetuximab,
is driving substantial research into further novel biologics.
There are currently six unconjugated antibodies approved in
oncology by the FDA and in excess of 80 in various stages of
clinical development (Reichert and Valge-Archer, 2007). In
common with small-molecule approaches to targeted cancer
therapy, antibody therapeutics have conventionally been
designed to target mitogenic or pro-survival pathways aberrantly
activated or differentially overexpressed in cancer cells as
compared with that in normal cells. Well-characterised examples
include members of the epidermal growth factor receptor
(EGFR) family, which have been targeted both by small molecules,
which effect receptor tyrosine kinase inhibition, and by antibodies,
which inhibit signalling by binding to the extracellular domain
of the receptor (e.g., cetuximab (Her-1) and trastuzumab
(Her-2neu)).
Antibodies targeting such functional tumour antigens
have principally been designed to achieve their effects through
Fab-mediated mechanisms. By necessity, antibody engineering
efforts have, therefore, focussed on optimising antibody–
antigen interactions, for example, antibody affinity. A variety
of technologies have been used to generate humanised or
human antibodies to decrease immunogenicity (Almagro and
Fransson, 2008).
Full-length monoclonal antibodies, including those targeting
functional antigens, also have the capacity to act by additional
mechanisms via their Fc domain, recruiting components of the
host immune system to elicit cancer cell death. There are now
compelling data indicating a significant contribution of such
mechanisms to clinical efficacy. These data are accompanied by an
increased understanding of the antibody biology involved in these
processes. The potential to engage specific components of the
immune system has become central to the rational design of novel
antibody therapeutics to exploit Fc-mediated effects more fully.
The focus of antibody drug discovery has, therefore, shifted
somewhat in recent years, away from Fab generation, where many
of the challenges have been met, and towards Fc engineering.
Optimising the engagement of the immune system has the
potential to augment the efficacy of antibodies directed against
functional cancer cell antigens. Moreover, it presents the prospect
of designing antibodies against non-functional tumour antigens to
achieve efficacy wholly through Fc-mediated effects. This repre-
sents a unique opportunity to broaden substantially the range of
antibody-based cancer therapeutics. Well-characterised functional
tumour antigens (predominantly growth factor receptors) amen-
able to targeting by antibodies are scarce and many have now been
intensively assessed either pre-clinically or clinically. In contrast,
poorly characterised tumour antigens with unknown mitogenic or
pro-survival functions, but with favourable tumour expression
profiles, are comparatively abundant but have yet to be fully
exploited. Previously described examples of tumour-associated
antigens within this category include PSMA, 5T4, folate receptor-a,
CEA and mesothelin (Reichert and Valge-Archer, 2007). Expres-
sion profiling strategies to identify antigens differentially
expressed in tumours continue to expand this repertoire further.
The successful application of new approaches and technologies
to target these antigens constitutes a new challenge in the evolution
of antibody therapeutics in oncology.
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that will be required to develop such antibodies as compared with
those used to generate antibodies to inhibit functional tumour
antigens. The development of antibody therapies against targets
such as Her-1 and Her-2 was driven, at least in part, by their
capacity to elicit direct and measurable effects on tumour cells
induced by antibody binding both in vitro and in murine models
(reviewed by Pegram and Slamon, 2000; Baselga, 2001). Studies
using transgenic mouse models, inactive isotypes or depletion of
specific immune cell populations have subsequently helped to
dissect the contribution of Fc-mediated mechanisms to their
efficacy (Clynes et al, 2000; Spiridon et al, 2004). However, the
primary antiproliferative and other biological effects mediated by
the Fab portion of the antibody could reasonably be expected to
effect therapeutic gain and were the basis for the therapeutic
hypothesis justifying entry into clinical trials. In contrast, the
development of antibodies against novel targets, which may
depend more, or solely, on Fc-mediated mechanisms of action,
requires in vitro and in vivo screening techniques convincingly
predictive for efficacy in humans. Our current screening cascades
are confounded by immunological differences between rodents
and humans, and our limited understanding of the parameters that
influence how the interactions between target cells, antigen
epitopes, antibodies, Fc receptors and effector cells lead to cell
kill. Success will depend on addressing these current knowledge
gaps and technological barriers, ultimately to understand the key
antigen and antibody characteristics that are required to achieve
the optimised and tailored recruitment of specific immune system
components, and to unleash their therapeutic power.
Fc-MEDIATED MECHANISMS OF IMMUNE SYSTEM
ENGAGEMENT
The mechanisms by which Fc–Fc-receptor interactions regulate
immune responses to effect tumour cell death have been
extensively reviewed elsewhere (Nimmerjahn and Ravetch, 2008).
Briefly, therapeutic antibodies bound to tumour-cell surface
antigens have the potential to elicit immune-mediated cell death
either by engaging immune system effector cells or by activating
the complement cascade.
Antibody-dependent cell cytotoxicity (ADCC) involves recruit-
ment of immune effector cells (e.g., natural killer (NK) cells and
macrophages) to kill cancer cells directly by a variety of means,
including local release of granzymes and perforins. Similarly,
antibody-dependent cell phagocytosis (ADCP) involves recruit-
ment of phagocytic cells (e.g., macrophages) by virtue of their
Fc-receptor expression, culminating in phagocytosis and death of
the target cell. As discussed below, ADCP by cells with antigen
presentation capacity also has the potential to engage the adaptive
immune system. Understanding of resistance mechanisms to
ADCC and ADCP beyond downregulation of the target is
limited, although expression of FcgRIIb by melanoma cells
has been proposed to decrease their susceptibility to ADCC
(Cassard et al, 2008).
Human Fcg receptors are expressed by a range of immune cell
populations, including B cells, dendritic cells, macrophages, mast
cells, NK cells and neutrophils (Desjarlais et al, 2007). They can be
grouped according to their signalling transduction activities when
engaged by their cognate Fc domain, as summarised in Table 1.
Engagement of activatory Fc receptors results in phosphorylation
of the cytoplasmic ITAM domain and subsequent signal transduc-
tion cascade, culminating in activation of cellular functions
including ADCC and phagocytosis. In contrast, engagement of
the inhibitory receptor FcgRIIb results in phosphorylation of its
cytoplasmic ITIM domain and downregulation of the effector
response. The physiological roles of FcgRIIb are varied and
complex. Within the context of a negative regulator of immune
activation, it plays a crucial role in regulating B-cell
activity, modulating humoral tolerance and regulating plasma-cell
survival. Of particular relevance to antibody therapeutics, multiple
studies have also served to illustrate the importance of this
receptor in regulating both innate and adaptive immune systems
(reviewed by Nimmerjahn and Ravetch, 2008). The consequence of
immune cell engagement by antibodies is tightly controlled by the
balance of activatory and inhibitory Fc-receptor binding. The
importance of this differential binding of antibodies is discussed
further below.
Table 1 Fcg-receptors in human and mouse
Activatory Relative
Structural
signalling Allelic
Putative
functional
murine
Principal effector-cell
expression profile
a
Receptor CD inhibitory affinity for IgG components variants analogue mU DC N B NK
Human
FcgRI CD64 Activatory High
b ITAM (associated g-chain) FcgRI KKK
Fcg RIIa CD32a Activatory Low/Mod ITAM (integral) 131H
131R
FcgRIV KKK
Fcg RIIb CD32b Inhibitory Low/Mod ITIM (integral) 232I
232T
FcgRIIb KKK K
Fcg RIIc CD32c Activatory Low/Mod ITAM (integral) KK K
Fcg RIIIa CD16a Activatory Low/Mod ITAM (associated g-chain) 158V
158F
FcgRIII KK K
Fcg RIIIb CD16b Activatory Low/Mod Non-signalling (gpi-linked) NA1
NA2
K
Mouse
FcgRI Activatory High ITAM (associated g-chain) KK
FcgRIIb Inhibitory Low/Mod ITIM (integral) KKK K
FcgRIII Activatory Low/Mod ITAM (associated g-chain) KKK K
FcgRIV Activatory Low/Mod ITAM (associated g-chain) KKK
Abbreviations: DC¼dendritic cell; ITAM¼immunoreceptor tyrosine-based activatory motif; ITIM¼immunoreceptor tyrosine-based inhibitory motif; mF¼macrophage;
N¼neutrophil, B¼B cell; NK¼natural killer cell.
aFc-receptor expression is variable and can be modulated on certain cell populations, for example, by cytokine signalling and
activation status. Data shown are intended to indicate expression on key effector-cell populations involved in Fc-mediated immune responses.
bHuman and murine FcgRI have
high affinity for monomeric IgG irrespective of antigen binding.
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individual Fc receptors, which is reflected by the capacity of active
isotypes to recruit immune effector cells efficiently based on their
Fcg receptor expression profile. IgG1 and IgG3 are considered the
principal active human isotypes based on their comparative
affinity for activatory receptors. In the murine setting, IgG2a and
IgG2b represent the most active functional isotypes (Dijstelbloem
et al, 2001; Nimmerjahn et al, 2005a).
Complement-dependent cytotoxicity (CDC) results in the death
of antibody-bound cells as a result of activation of the classical
complement cascade. The process is initiated by the binding of c1q
to the Fc portion of antigen-bound antibody and culminates in the
production of a membrane attack complex in the target cell
membrane, causing cell lysis. Resistance to CDC by membrane
overexpression of complement regulatory proteins is evident in
some tumour types (Yan et al, 2008).
DATA SUPPORTING THE ROLE OF Fc-MEDIATED
MECHANISMS IN ANTIBODY EFFICACY
An increasing body of data derived from both murine and clinical
studies has helped to dissect the contribution of Fc-mediated
activities to clinical efficacy.
Transgenic mouse models in which antibody–receptor engage-
ment is modified or effector-cell activity is reduced have been
extensively used for this purpose. For example, the efficacy of
trastuzumab against breast cancer xenografts is dramatically
inhibited in transgenic mice in which functional Fc receptors are
not expressed, and is enhanced in models using mice deficient for
the inhibitory Fc receptor FcgRIIB (Clynes et al, 2000). Further-
more, F(ab0)2 fragments of trastuzumab show poor in vivo efficacy
against breast tumour xenografts as compared with full-length IgG,
despite having similar in vitro antiproliferative and proapoptotic
effects (Spiridon et al, 2004).
The most compelling data supporting the role of Fc-mediated
mechanisms come from retrospective analyses of clinical data.
These studies have generally focussed on attempting to correlate
clinical response with Fc-receptor polymorphisms known to
modulate antibody–receptor engagement. Specifically, FcgRIIIA
158V/V homozygosity confers approximately five-fold increase in
affinity for IgG1 compared with the FcgRIIIA 158F/F genotype and
NK cells isolated from donors with the FcgRIIIA 158V/V genotype
show superior NK-mediated ADCC capacity in vitro (Dall’Ozzo
et al, 2004). The clinical correlate of this observation was initially
described in retrospective analyses of clinical responses to
rituximab in which patients harbouring the FcgRIIIA 158V/V
genotype showed superior response to rituximab in the treatment
of non-Hodgkin’s lymphoma compared with homozygous F/F or
heterozygous F/V patients (Cartron et al, 2002). Further studies
have consolidated these findings and, in addition, have demon-
strated the importance of an additional polymorphism, FcgRIIA
131H/H (Weng and Levy, 2003), although the mechanism by which
this polymorphism achieves superior engagement is not yet fully
defined, as it does not show differential IgG1 affinity (Desjarlais
et al, 2007). More recently, data relating to the prognostic
significance of these polymorphisms in response to other
antibodies, including trastuzumab (Musolino et al, 2008) and
cetuximab (Bibeau et al, 2009), have been reported, which indicate
similar trends. However, it should be noted that such data are not
without controversy. Studies to date have used relatively small
sample sizes and retrospective data analysis. Furthermore,
apparently contradictory data describe the FcgRIIIA 158F/F
genotype as being favourable for cetuximab response (Zhang
et al, 2007). Prospective clinical trials with larger patient numbers
are required to validate the role of Fc-mediated mechanisms. This
will inform a variety of strategies aimed at maximising patient
response, including genotyping patients to predict response and
development of next-generation antibodies, which achieve
efficacy irrespective of Fc-receptor polymorphism status. Such
analysis may be confounded by other, independent factors that
influence responses to targeting functional tumour antigens, for
example, PI3-kinase mutation status in trastuzumab therapy
(Junttila et al, 2009) and K-ras mutation status in cetuximab
treatment (Bibeau et al, 2009).
IN VITRO CHARACTERISATION OF ANTIBODY
REPERTOIRES
Repertoires of antibodies against a specific candidate target can be
generated by a variety of methods. Variable regions derived from
such techniques can readily be grafted onto antibody framework
constructs to generate repertoires of full-length antibodies of the
desired isotype, and screened for properties including antigen
affinity and specificity. Individual antibodies must also screened
for ADCC activity, as repertoires can contain antibodies with
significant differences in apparent ADCC potency, despite being
specific for the same antigen and sharing properties of identical Fc
and framework sequences, and similar binding and affinity profiles
(Griggs et al, unpublished data). Such differences can be identified
using a variety of robust human in vitro models for assessing CDC
or ADCC activity. The lysis of target cells endogenously expressing
the antigen of interest can readily be detected after co-incubation
with human serum or purified human complement (CDC
detection) or purified human PBMCs or NK cells (ADCC
detection). Despite their utility in providing a means of confirming
the potential for ADCC or CDC competence, such assays are not
without their limitations. While they provide a system in which
human target and effector cells and human format antibodies
interact, little is known about the physiological relevance of the
conditions used, particularly the ratio of effector and target cells
employed, which is typically higher than might reasonably be
expected to be achieved in vivo. The relevance of the effector cells
used in ADCC assays in vitro also remains to be defined: NK cells
are most commonly employed in this context but are not
necessarily the most important effector-cell population for all
tumours in vivo. Furthermore, as they do not express the
inhibitory receptor FcgRIIb (CD32b), positive data from assays
using NK effectors may be misleading as, for example, they would
fail to account for the effects of inhibitory Fc-receptor interactions
on other effector-cell populations. Significantly, the development
of parallel in vitro ADCC assays using murine format antibodies
and murine effector cells has proven challenging. This complicates
the transition from in vitro to in vivo screens in the drug discovery
process as human format antibodies identified in vitro may not
elicit equivalent engagement of the murine immune system and
therefore may not represent the most appropriate tools for target
validation, nor necessarily constitute the lead candidates for
further development. This is particularly problematic when
attempting to validate poorly-characterised antigens and models.
One of the major determinants of the heterogeneity in potency
seen within antibody repertoires is likely to involve the specific
epitopes targeted. Surprisingly little attention has been given to the
importance of epitope selection and the identification of optimal
epitope characteristics, despite increasing evidence that targeting
particular epitopes may have crucial implications for antibody
efficacy. For example, the novel anti-CD20 antibody ofatumumab,
currently in phase-III clinical trials and under review by the US
FDA, is significantly more potent at inducing CDC than rituximab.
Ofatumumab recognises a distinct epitope in close proximity to
the plasma membrane, which is claimed to permit a more efficient
localisation of complement components on the cell surface (Ruuls
et al, 2008). Novel approaches have begun to address the potential
of targeting multiple epitopes by combining several monoclonal
antibodies against a single antigen. Such a ‘polymonoclonal’
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(Tolstrup et al, 2006), and this approach has progressed to clinical
evaluation in several non-oncological disease areas. Encouraging
preclinical data relating to polymonoclonal targeting of EGFR in
oncology have recently been reported (Koefoed et al, 2009).
An additional consideration relating to the use of in vitro assays
to select candidate antibodies for progression is that they fail to
account for antibody properties which may influence tumour
penetration in vivo. These properties remain to be fully
defined, but are likely to include both physical and biochemical
characteristics (Beckman et al, 2007).
USES AND CURRENT LIMITATIONS OF MURINE
MODELS
The transitioning of candidate therapeutic antibodies into
meaningful in vivo efficacy assays remains problematic, principally
due to lack of equivalence between human and murine immune
systems. Such issues appear to extend beyond species differences
in Fc receptor repertoires and antibody isotype activities, as
immune interactions may also differ between antigens.
Notwithstanding these difficulties, murine models can represent
useful tools for target validation and proof-of-concept studies for
novel tumour-specific antigens. Antitumour activity in ADCC-
and/or CDC-competent models can be compared to that in models
where Fc-mediated responses are impaired, to define the
contribution of the immune system (Clynes et al, 2000). However,
such studies do not necessarily lead to identification of the optimal
human therapeutic candidate for progression into clinical trials.
Significantly more sophisticated murine models may be required
to achieve this aim and to avoid the risk of identifying antibodies
with murine potency but sub-optimal capacity for human immune
system interaction. Reconstituted SCID mice, in which human
effector cells are engrafted into immunodeficient mice, have been
employed as a means of artificially representing the human
immune system in vivo (Shultz et al, 2007). Despite recent
advances in the use of these models to evaluate ADCC activity (Ito
et al, 2008), they have a range of limitations and do not represent a
true reproduction of human effector-cell populations. As an
alternative, transgenic mice expressing human FcgRIIIa human
in the absence of murine FcgRI and FcgRIII are now available. The
ultimate tool for the modelling of Fc-mediated ADCC by human
effector cells may be a murine model fully transgenic for all human
Fcg receptors and devoid of endogenous murine Fc receptors.
Consideration must also be given to non-human primate
immune system characteristics if such species are to be used for
meaningful preclinical toxicology studies. Despite recent progress,
our understanding of the equivalence of human and primate
Fc-receptor engagement remains incomplete. The resolution of
this issue will become increasingly important as antibodies
with optimised immune activatory capacity are developed,
particularly if target antigens show some degree of normal tissue
expression.
TECHNOLOGIES FOR ENHANCEMENT OF Fc EFFECTS
A variety of technologies have been developed aimed at optimising
the antibody–immune system interaction to maximise Fc-
mediated effects. The ultimate aim of such approaches is the
development of antibodies with novel, tailored Fc regions able to
elicit effects via one or more selected mechanisms of action that
retain the favourable properties of specificity, affinity, low
immunogenicity and acceptable pharmacokinetics. The main focus
of several of these approaches has been to achieve increased Fc
affinity for activatory Fc-receptors and/or decreased affinity for
inhibitory receptors on immune effector cells to achieve enhanced
ADCC. Within this context, strategies can be grouped into those
which modify antibody glycosylation and those identifying key Fc
amino-acid sequences for mutagenesis.
Antibody glycosylation has emerged as a major determinant of
Fc-receptor affinity and this has been exploited by several
technologies. In particular, antibodies with reduced fucosyl
moieties show pronounced increase in potency in in vitro assays
of ADCC using human effector cells (Shields et al, 2002). Crucially,
it has been reported that low-fucose rituximab elicits enhanced
ADCC irrespective of the FcgRIIIA 158V/F polymorphism (Niwa
et al, 2004). Several afucosylated antibodies have now entered
clinical trials (Table 2). The N-glycosylation of Fc domains with
other moieties, including sialic acid, mannose and bisecting
N-acetylglucosamine also has a dramatic effect on Fc–Fc-receptor
interaction and is the subject of further technological approaches
(Raju, 2008). It remains to be established whether these
technologies augment ADCC to equivalent degrees in human and
murine settings. Indeed, there are currently conflicting data on
whether afucosylation of human antibodies increases binding to
murine FcgRIV. Although it is possible that such interactions may
be antibody-specific, this would be unexpected. Failure of
afucosylation to alter interactions between human antibodies and
murine Fc receptors would render the predictive utility of in vivo
murine screens using such human antibodies questionable.
Fc mutational engineering presents an alternative approach to
improving both ADCC and CDC potency. A variety of amino-acid
residues that are critical for Fc–FcR interactions have been
identified and modified to achieve increased binding to FcgRIIIa
and/or decreased binding to FcgRIIb. Combinations of amino-acid
substitutions have been applied to clinically validated antibodies,
resulting in increased ADCC potency in vitro exceeding two orders
of magnitude and increasing target-cell depletion in vivo (Lazar
et al, 2006). Combining optimised mutational and glycosylation
approaches does not appear to confer an additive advantage
(Masuda et al, 2007). Amino-acid residues influencing C1q binding
can also be manipulated to alter CDC activity, although the
contribution of CDC to clinical efficacy is much less well described
than that of ADCC. A variety of approaches have sought to
combine enhanced ADCC and CDC activities, including Fc isotype
domain shuffling (Natsume et al, 2008).
Ravetch and co-workers have defined an ‘A:I ratio’ as a means of
ranking antibody Fc-mediated functional activity by calculating
Table 2 Clinical-phase anticancer antibodies incorporating Fc modifications
Ab name Target Technology Clinical phase Company
XmAb2513 CD30 XmAb Fc
a Phase I Xencor
MDX-1401 CD30 Potelligent
b Phase I Medarex
BIW-8962 Ganglioside GM2 receptor Potelligent Phase I/II Kyowa Hakko Kirin (Biowa)
Afutuzumab CD20 GlycoMAb
c Phase II Roche (Glycart)
R7160 EGFR GlycoMAb Phase I Roche (Glycart)
Abbreviation: EGFR¼epidermal growth factor receptor.
aFc protein engineering to increase Fc receptor engagement.
bFUT8-knockout CHO cells producing non-fucosylated
antibodies with increased Fc-receptor engagement.
cGenetically engineered cells producing antibodies bearing bisected non-fucosylated oligosaccharides with increased receptor
engagement.
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receptors in biochemical assays. Striking data have been reported
that correlate the A:I ratio of particular murine antibody isotypes
against a common antigen with their capacity to achieve ADCC-
mediated tumour inhibition in vivo. For example, the anti-gp75
antibody, TA99, is highly efficacious in an experimental melanoma
metastasis model as a murine IgG2a format (high A:I), but
demonstrates sequential loss of efficacy when used in IgG2b, IgG1
and IgG3 formats (decreasing A:I) (Nimmerjahn and Ravetch,
2005b). Such studies highlight the importance of isotype choice for
eliciting Fc-mediated mechanisms. The extension of the A:I
hypothesis into a differentiating screen for optimal drug candi-
dates from within a panel of human antibodies with a common
isotype is an enticing possibility.
There is renewed interest in IgEs for passive immunotherapy as
IgEs have a natural affinity for FceRI, which is 2–5 orders of
magnitude greater than IgGs for their cognate receptors. IgEs can
trigger ADCC and ADCP activity by eosinophils, mast cells and
macrophages (Jensen-Jarolim et al, 2008).
Beyond antibody engineering techniques, Fc-mediated responses
may also be augmented by increased activation, expansion and
recruitment of effector cells. Approaches include administration of
recombinant cytokines (e.g., interleukin-2 (IL-2), IFN-a and GM-
CSF) or immunomodulatory drugs (e.g., thalidomide analogues).
For example, preclinical observations (Lopes de Menezes et al,
2007; Reddy et al, 2007) have described a synergistic effect of IL-2
in combination with rituximab in both retuximab-sensitive and
retuximab-insensitive non-Hodgkin lymphoma (NHL) xenograft
models. However, a phase-II clinical study showed no benefit of
rituximab IL-2 combination therapy in retuximab-refractory NHL
(Khan et al, 2006).
IDENTIFICATION OF KEY EFFECTOR-CELL
POPULATIONS
The role of particular effector-cell populations in achieving ADCC
in vivo remains controversial. While NK cells and macrophages
share some common Fc-receptors, it understates the complexity of
immunotherapeutic approaches to assume that a generic approach
of increasing antibody affinity for activatory receptors will
necessarily suffice for achieving optimal effector cell engagement.
For example, NK cells are generally believed to be largely
responsible for Fc-mediated efficacy against haematological
tumours, yet reportedly show very poor penetration into solid
tumours. However, this does not necessarily justify an emphasis on
optimising macrophage engagement, as tumour-associated macro-
phages have the potential to exert pro-tumorigenic effects.
Furthermore, data are emerging suggesting that antibody treat-
ment may enhance tumour infiltration of NK cells. Thus, Fc-
mediated antibody activities must be viewed in the context of the
tumour microenvironment, which cannot be recapitulated in vitro.
Further understanding of the role of specific effector-cell popula-
tions in particular tumour types is required to elucidate the
optimal effector-cell engagement strategy for solid-tumour
therapy, which may not prove the same for all tumour types.
The complexity of the in vivo environment is well illustrated by
work with anti-CD20 monoclonal antibodies where ADCC was
shown in a murine model to be the main mechanism of action in
most cellular compartments, but CDC drove B-cell depletion in
marginal zones (Gong et al, 2005).
ENGAGING THE ADAPTIVE IMMUNE SYSTEM
The engagement of the adaptive immune system against tumour
antigens represents a long-standing goal in cancer therapy. The
development of optimised passive immunotherapies may offer the
potential to achieve such an adaptive immune switch. Enhancing
the antibody-mediated recruitment of effector cells with antigen-
presentation capacity, for example, dendritic cells, may lead to
presentation of tumour antigens in an appropriate context to
engage a T-cell-driven response. Preliminary data appear to
confirm the potential of this approach and there is considerable
interest in defining the conditions that need to be met to break
immune tolerance to tumour antigens. Of particular interest are
recent observations that describe the process of ‘cross-priming’ of
professional antigen-presenting cells. Phagocytosis as a conse-
quence of Fc-receptor engagement can result in preferential
presentation of tumour-associated antigens by MHC class-I rather
than MHC class-II, potentially activating CD8-positive effector T
cells with tumour-antigen specificity (reviewed by Desjarlais et al,
2007). Intriguingly, the bias towards MHC class-II presentation
appears to be driven by decreased inhibitory Fc-receptor binding.
This raises the possibility that selecting antibodies with favourable
A:I properties may achieve the dual benefit of enhanced ADCC and
enhanced adaptive immune system engagement.
It should be noted that the clinical use of antibodies with
putative Fc-mediated activity has not been without some toxicity
in patients. In common with all methods that seek to increase
Fc-mediated effects, the potential to increase toxicity should be
considered, particularly in the context of autoimmune complica-
tions that may arise where normal tissue expression of the antigen
occurs.
CONCLUDING REMARKS
Convincing evidence of the important role of Fc-mediated
mechanisms of action in the clinical efficacy of antitumour
antibodies now exists. Such evidence reveals not only the potential
to augment the clinical efficacy observed to date against existing
targets, but also the opportunity to exploit a range of other cancer
targets with antibody therapeutics designed to achieve their effects
predominantly through Fc-mediated mechanisms. There remain
significant challenges within the drug discovery process to
achieving this aim, most notably, the development of optimal
in vitro and in vivo screening methods, an improved consideration
of the importance of epitope selection and a better understanding
of events at the tumour–immune system interface. Success in
meeting these challenges will achieve a new generation of
therapeutics and will represent an advance as important as
previous technological achievements in antibody engineering that
have enabled their successful clinical use.
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